$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-Q Financial Statement

#000106282216000073 Filed on August 04, 2016

Income Statement

Concept	2016 Q3	2016 Q2	2015 Q2
Revenue	$27.72M	$20.09M	$376.0K
YoY Change	4797.0%	5242.82%	-44.38%
Cost Of Revenue	$0.00	$0.00
YoY Change
Gross Profit	$27.72M	$20.09M
YoY Change
Gross Profit Margin	100.0%	100.0%
Selling, General & Admin	$12.26M	$8.416M	$6.300M
YoY Change	127.09%	33.59%	26.0%
% of Gross Profit	44.24%	41.89%
Research & Development	$52.53M	$48.22M	$20.77M
YoY Change	127.31%	132.15%	-1.97%
% of Gross Profit	189.53%	240.01%
Depreciation & Amortization	$500.0K	$500.0K	$200.0K
YoY Change	400.0%	150.0%	-66.67%
% of Gross Profit	1.8%	2.49%
Operating Expenses	$62.65M	$57.11M	$27.06M
YoY Change	82.96%	111.02%	1.03%
Operating Profit	-$34.93M	-$37.02M	-$26.69M
YoY Change	3.73%	38.72%	2.21%
Interest Expense	$1.646M	$1.638M	$1.655M
YoY Change	-2.43%	-1.03%	263.74%
% of Operating Profit
Other Income/Expense, Net	$564.0K	$547.0K	$269.0K
YoY Change	587.8%	103.35%	-50.0%
Pretax Income	-$36.02M	-$38.11M	-$28.10M
YoY Change	2.03%	35.63%	8.08%
Income Tax
% Of Pretax Income
Net Earnings	-$36.02M	-$38.11M	-$28.07M
YoY Change	2.08%	35.76%	7.86%
Net Earnings / Revenue	-129.94%	-189.72%	-7466.49%
Basic Earnings Per Share			-$0.27
Diluted Earnings Per Share	-$346.5K	-$367.1K	-$0.27
COMMON SHARES
Basic Shares Outstanding	103.9M shares	103.8M shares	103.6M shares
Diluted Shares Outstanding			103.6M shares

Balance Sheet

Concept	2016 Q3	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$395.6M	$429.4M	$282.1M
YoY Change	54.53%	52.22%	258.91%
Cash & Equivalents	$38.77M	$38.41M	$9.744M
Short-Term Investments	$356.8M	$391.0M	$272.3M
Other Short-Term Assets	$2.443M	$9.071M	$7.151M
YoY Change	-77.7%	26.85%	-2.6%
Inventory
Prepaid Expenses
Receivables	$738.0K	$1.018M	$316.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$398.7M	$439.5M	$313.8M
YoY Change	38.0%	40.04%	262.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.85M	$20.35M	$684.0K
YoY Change	2397.36%	2875.15%	-98.25%
Goodwill	$44.54M	$44.54M	$44.54M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$53.36M	$53.36M	$53.36M
YoY Change	0.0%	0.0%	-0.37%
Long-Term Investments
YoY Change
Other Assets	$454.0K	$430.0K	$3.581M
YoY Change	-87.02%	-87.99%	2884.17%
Total Long-Term Assets	$118.2M	$118.7M	$102.2M
YoY Change	15.67%	16.17%	-25.64%
TOTAL ASSETS
Total Short-Term Assets	$398.7M	$439.5M	$313.8M
Total Long-Term Assets	$118.2M	$118.7M	$102.2M
Total Assets	$516.9M	$558.1M	$416.0M
YoY Change	32.16%	34.18%	85.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$41.55M	$28.23M	$11.29M
YoY Change	154.02%	149.98%	35.22%
Accrued Expenses	$32.91M	$23.95M	$10.81M
YoY Change	120.65%	121.62%	-0.73%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$16.79M	$17.29M	$19.26M
YoY Change	-10.62%	-10.21%	979.92%
Total Short-Term Liabilities	$170.1M	$131.0M	$43.57M
YoY Change	228.41%	200.64%	98.99%
LONG-TERM LIABILITIES
Long-Term Debt	$85.04M	$84.91M	$87.50M
YoY Change	-2.81%	-2.96%	354.43%
Other Long-Term Liabilities	$2.500M	$14.04M	$23.04M
YoY Change	-89.37%	-39.06%	-33.84%
Total Long-Term Liabilities	$87.54M	$98.95M	$110.5M
YoY Change	-21.15%	-10.49%	104.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$170.1M	$131.0M	$43.57M
Total Long-Term Liabilities	$87.54M	$98.95M	$110.5M
Total Liabilities	$331.8M	$340.8M	$184.5M
YoY Change	71.72%	84.73%	71.78%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.218B	-$1.182B	-$1.160B
YoY Change	1.86%	1.86%	9.39%
Common Stock	$104.0K	$104.0K	$104.0K
YoY Change	0.0%	0.0%	-79.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.368M	$3.368M	$2.747M
YoY Change	22.61%	22.61%	14.94%
Treasury Stock Shares	306.0K shares	306.0K shares	237.0K shares
Shareholders Equity	$185.2M	$217.3M	$231.5M
YoY Change
Total Liabilities & Shareholders Equity	$516.9M	$558.1M	$416.0M
YoY Change	32.16%	34.18%	85.65%

Cashflow Statement

Concept	2016 Q3	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	-$36.02M	-$38.11M	-$28.07M
YoY Change	2.08%	35.76%	7.86%
Depreciation, Depletion And Amortization	$500.0K	$500.0K	$200.0K
YoY Change	400.0%	150.0%	-66.67%
Cash From Operating Activities	-$35.20M	-$47.90M	-$32.20M
YoY Change	38.58%	48.76%	63.45%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$500.0K
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$33.90M	$61.60M	$800.0K
YoY Change	-56.54%	7600.0%	-33.33%
Cash From Investing Activities	$33.90M	$61.50M	$300.0K
YoY Change	-56.43%	20400.0%	-75.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.700M	0.000	-400.0K
YoY Change	-525.0%	-100.0%	0.0%
NET CHANGE
Cash From Operating Activities	-35.20M	-47.90M	-32.20M
Cash From Investing Activities	33.90M	61.50M	300.0K
Cash From Financing Activities	1.700M	0.000	-400.0K
Net Change In Cash	400.0K	13.60M	-32.30M
YoY Change	-99.23%	-142.11%	70.9%
FREE CASH FLOW
Cash From Operating Activities	-$35.20M	-$47.90M	-$32.20M
Capital Expenditures	$0.00	$0.00	-$500.0K
Free Cash Flow	-$35.20M	-$47.90M	-$31.70M
YoY Change	39.68%	51.1%	60.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.70
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1741000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	103865713	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	LEXICON PHARMACEUTICALS, INC./DE
CY2016Q2	lxrx	Buildings Collateral BuildingsCollateral	59200000	USD
CY2015Q2	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	-12000	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1741000	USD
CY2016Q2	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	478000	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1443000	USD
CY2016Q2	lxrx	Convertible Debt Instrument Interest Rate Stated Percentage ConvertibleDebtInstrumentInterestRateStatedPercentage	0.0525
CY2007Q2	lxrx	Holdings Contribution To Icon HoldingsContributionToIcon	45000000	USD
CY2014Q4	lxrx	Ipsen Maximum Regulatory And Commercial Milestones IpsenMaximumRegulatoryAndCommercialMilestones	34000000	USD
CY2014Q4	lxrx	Ipsen Maximum Sales Milestones IpsenMaximumSalesMilestones	72000000	EUR
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Committee Deliverable IpsenRevenueAllocatedtoCommitteeDeliverable	100000	USD
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Development Deliverable IpsenRevenueAllocatedtoDevelopmentDeliverable	1700000	USD
CY2014	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	21200000	USD
	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	1400000	USD
	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	2000000	USD
	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	200000	USD
	us-gaap	Licenses Revenue LicensesRevenue	38000	USD
	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonusand Restricted Stock Grantsin Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusandRestrictedStockGrantsinPeriodWeightedAverageGrantDateFairValue	13.96
	lxrx	Sharebased Compensation Arrangementby Sharebased Payment Award Stock Bonusand Restricted Stock Grantsin Period Shares SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStockGrantsinPeriodShares	11456	shares
CY2015Q2	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	920000	USD
CY2010Q3	lxrx	Lexicon Paid Holdings Cash LexiconPaidHoldingsCash	10000000	USD
	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	1769000	USD
CY2007Q2	lxrx	Lexicon Received Cash From Holdings LexiconReceivedCashFromHoldings	15000000	USD
CY2007Q2	lxrx	Lexicon Sold Shares To Holdings LexiconSoldSharesToHoldings	1092946	shares
CY2016Q1	lxrx	Real Estate Selling Price RealEstateSellingPrice	21200000	USD
CY2015Q4	lxrx	Reclassificationof Debt Issuance Costs Impactto Current Portionof Longterm Debt ReclassificationofDebtIssuanceCostsImpacttoCurrentPortionofLongtermDebt	39000	USD
CY2015Q4	lxrx	Reclassificationof Debt Issuance Costs Impactto Longterm Debt ReclassificationofDebtIssuanceCostsImpacttoLongtermDebt	2800000	USD
CY2015Q4	lxrx	Reclassificationof Debt Issuance Costs Impactto Other Assets ReclassificationofDebtIssuanceCostsImpacttoOtherAssets	2900000	USD
CY2015Q4	lxrx	Sanofi Commercialization Costs Fundedby Lexicon Maximum Amount SanofiCommercializationCostsFundedbyLexiconMaximumAmount	100000000	USD
CY2015Q4	lxrx	Sanofi Developmentand Regulatory Milestone Payments SanofiDevelopmentandRegulatoryMilestonePayments	430000000	USD
CY2015Q4	lxrx	Sanofi Revenue Allocatedto Development Deliverable SanofiRevenueAllocatedtoDevelopmentDeliverable	113800000	USD
CY2016Q2	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	984000	USD
CY2015Q1	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
CY2016Q2	lxrx	Land Collateral LandCollateral	2700000	USD
CY2015Q4	lxrx	Sanofi Revenue Allocatedto Funding Deliverable SanofiRevenueAllocatedtoFundingDeliverable	59400000	USD
CY2015Q4	lxrx	Sanofi Revenue Allocatedto License Deliverable SanofiRevenueAllocatedtoLicenseDeliverable	126800000	USD
	lxrx	Sanofi Revenue Recognized SanofiRevenueRecognized	31700000	USD
CY2015Q4	lxrx	Sanofi Sales Milestone Payments SanofiSalesMilestonePayments	990000000	USD
CY2015Q4	lxrx	Sanofi Upfront Payment SanofiUpfrontPayment	300000000	USD
	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	1830000	USD
CY2015Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	868000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1972000	USD
CY2016Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	973000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1962000	USD
CY2010Q3	lxrx	Symphon Fair Value Of Base And Contingent Payments SymphonFairValueOfBaseAndContingentPayments	45600000	USD
CY2010Q3	lxrx	Symphony Base Payment Discount Rate SymphonyBasePaymentDiscountRate	0.14
CY2012Q3	lxrx	Symphony Base Payment In Shares SymphonyBasePaymentInShares	1891074	shares
CY2012Q3	lxrx	Symphony Base Payment Obligation SymphonyBasePaymentObligation	35000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Discount Rate SymphonyContingentPaymentDiscountRate	0.18
CY2014Q4	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	5800000	USD
CY2015Q2	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	750000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Maximum SymphonyContingentPaymentMaximum	45000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Percentage SymphonyContingentPaymentPercentage	0.50
CY2014Q4	lxrx	Symphony Contingent Payment Total SymphonyContingentPaymentTotal	11500000	USD
CY2014Q4	lxrx	Symphony Contingent Paymentin Shares SymphonyContingentPaymentinShares	666111	shares
CY2010Q3	lxrx	Symphony Payment In Stock Limitation SymphonyPaymentInStockLimitation	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Payment SymphonyRegulatoryApprovalPayment	15000000	USD
CY2010Q3	lxrx	Symphony Regulatory Approval Percentage Limit SymphonyRegulatoryApprovalPercentageLimit	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Reduction Percentage SymphonyRegulatoryApprovalReductionPercentage	0.50
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	19725000	USD
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	28225000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	911000	USD
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1018000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24757000	USD
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23950000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	59428000	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	58855000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-219000	USD
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	336000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1397646000	USD
CY2016Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1402190000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3741000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3792000	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1800000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3700000	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2000000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3800000	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4000	USD
CY2016Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	241000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	250000	USD
CY2015Q4	us-gaap	Assets Assets	651960000	USD
CY2016Q2	us-gaap	Assets Assets	558134000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	532400000	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	439454000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	137266000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9744000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	202989000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38410000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-127522000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-164579000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	104000	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	104000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27999000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55989000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-38073000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72440000	USD
CY2015Q2	us-gaap	Contracts Revenue ContractsRevenue	338000	USD
	us-gaap	Contracts Revenue ContractsRevenue	2130000	USD
CY2016Q2	us-gaap	Contracts Revenue ContractsRevenue	20001000	USD
	us-gaap	Contracts Revenue ContractsRevenue	32495000	USD
CY2016Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.442
CY2014Q4	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	118.4553
CY2016Q2	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	159800000	USD
CY2016Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0823
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	76499000	USD
CY2016Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	61528000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	109151000	USD
CY2016Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	92188000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18675000	USD
CY2016Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18675000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	601000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1037000	USD
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2016Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	24258000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-59000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12008000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	12000	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6307000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1443000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	-750000	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	17638000	USD
CY2015Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	18629000	USD
CY2015Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	22815000	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8416000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16814000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2016Q2	us-gaap	Goodwill Goodwill	44543000	USD
CY2016Q2	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	4000000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3326000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5818000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-719000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	107000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	371000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	31934000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-413000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2387000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1066000	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53357000	USD
CY2016Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53357000	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	1655000	USD
	us-gaap	Interest Expense InterestExpense	3357000	USD
CY2016Q2	us-gaap	Interest Expense InterestExpense	1638000	USD
	us-gaap	Interest Expense InterestExpense	3287000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3184000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3046000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	366110000	USD
CY2016Q2	us-gaap	Liabilities Liabilities	340801000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	651960000	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	558134000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	122957000	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	130992000	USD
CY2015Q2	us-gaap	Licenses Revenue LicensesRevenue	38000	USD
CY2016Q2	us-gaap	Licenses Revenue LicensesRevenue	88000	USD
	us-gaap	Licenses Revenue LicensesRevenue	88000	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1976000	USD
CY2016Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	17289000	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	100960000	USD
CY2016Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	84909000	USD
CY2016Q2	us-gaap	Mortgage Loans On Real Estate Carrying Amount Of Mortgages MortgageLoansOnRealEstateCarryingAmountOfMortgages	17300000	USD
CY2004Q2	us-gaap	Mortgage Loans On Real Estate New Mortgage Loans MortgageLoansOnRealEstateNewMortgageLoans	34000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1208000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-857000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70651000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-72104000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55663000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-91618000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-28074000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-56150000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-38112000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-72995000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	27064000	USD
	us-gaap	Operating Expenses OperatingExpenses	55383000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	57110000	USD
	us-gaap	Operating Expenses OperatingExpenses	103475000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-26688000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-53215000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-37021000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-70892000	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	10137000	USD
CY2016Q2	us-gaap	Other Assets Current OtherAssetsCurrent	9071000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	433000	USD
CY2016Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	430000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	75000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	161000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	39000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	555000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14367000	USD
CY2016Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14037000	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	269000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	422000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	547000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1184000	USD
CY2014Q4	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	3400000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	357000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	621000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	70505000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	219437000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	480000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	67000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	752000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	61000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	87500000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	147400000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	334000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21227000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20350000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	912000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	988000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20769000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41634000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48216000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	85218000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1108934000	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1181929000	USD
CY2015Q2	us-gaap	Revenues Revenues	376000	USD
	us-gaap	Revenues Revenues	2168000	USD
CY2016Q2	us-gaap	Revenues Revenues	20089000	USD
	us-gaap	Revenues Revenues	32583000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3741000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3792000	USD
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	318363000	USD
CY2016Q2	us-gaap	Short Term Investments ShortTermInvestments	390955000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	752000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	285850000	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	217333000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	284018000	USD
CY2015Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	231474000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	285850000	USD
CY2016Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	217333000	USD
	us-gaap	Stockholders Equity Other StockholdersEquityOther	61000	USD
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	237000	shares
CY2016Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	306000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	103756000	shares
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2747000	USD
CY2016Q2	us-gaap	Treasury Stock Value TreasuryStockValue	3368000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	357000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	621000	USD
CY2016Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2600000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	161000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	555000	USD
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	103608000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	103562000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	103830000	shares

Files In Submission

Name	View Source	Status
0001062822-16-000073-index-headers.html	Edgar Link	pending
0001062822-16-000073-index.html	Edgar Link	pending
0001062822-16-000073.txt	Edgar Link	pending
0001062822-16-000073-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lxrx-20160630.xml	Edgar Link	completed
lxrx-20160630.xsd	Edgar Link	pending
lxrx-20160630_cal.xml	Edgar Link	unprocessable
lxrx-20160630_def.xml	Edgar Link	unprocessable
lxrx-20160630_lab.xml	Edgar Link	unprocessable
lxrx-20160630_pre.xml	Edgar Link	unprocessable
lxrx630201610-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2016 Q3 Form 10-Q Financial Statement

#000106282216000073 Filed on August 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2016 Q3 Form 10-Q Financial Statement

#000106282216000073 Filed on August 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx